IRVINE, Calif., Feb. 15, 2007 (PRIME NEWSWIRE) -- "In the biotechnology arena, patent application is among the most imperative early indicators of a company's future promise," stated SmallCap Sentinel analyst D.R. Clark. "It's often among the first public steps a company can take in their pathway to market, and perhaps most importantly, it's one of the few public steps about technology being developed."
"Along these lines, CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) recently announced that the U.S. Patent and Trademark Office allowed CVBT's patent application for delivery injection of the company's protein drug candidate directly into the damaged heart muscle of patients suffering from coronary artery disease," continued Clark. CVBT's drug candidate contains a protein that stimulates the growth and production of new blood vessels, a process called angiogenesis.
Coronary heart disease, the most common form of cardiovascular disease, is the number one cause of death in the U.S. and Europe. The disease causes a reduction in blood flow that can result in chest pain, a heart attack or death. According to the American Heart Association, 15.8 million Americans suffer from coronary heart disease.
CVBT is a biopharmaceutical company developing formulations of its active pharmaceutical ingredient (API), Fibroblast Growth Factor-1, to treat a number of diseases characterized by inadequate blood flow to a tissue or organ. In addition to its cardiac clinical trial of FGF-1 (CVBT-141A) in Limited-Option Heart Patients, the Company is conducting FDA-authorized clinical trials of FGF-1 (CVBT-141B) for dermal wound healing in diabetics, and peripheral artery disease (CVBT-141C).
An informational report featuring Cardiovascular BioTherapeutics is available at: http://stockupticks.com/profiles/2-15-07.html.
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is online at http://www.SmallCapSentinel.com. The report addresses issues affecting biopharmaceutical companies including Merck Co. Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE), and AstraZeneca PLC ADS (NYSE:AZN).
Individuals may register to receive free future reports at: http://stockupticks.com/register.html.
Statements herein contain forward-looking statements and are subject to significant risks and uncertainties that affecting results. SmallCap Sentinel/StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid nineteen thousand two hundred dollars by CardioVascular BioTherapeutics Inc. for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.